| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 13426351 | Schizophrenia Research | 2019 | 4 Pages |
Abstract
This series of 10 cases of patients with refractory psychosis who responded to pimavanserin is an important new finding that has never been reported before. Controlled studies comparing clozapine and pimavanserin in refractory schizophrenia are warranted to confirm these clinical observations.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Henry A. Nasrallah, Rissa Fedora, Robert Morton,